INS and diabetes mellitus: In this study, we showed that systemic MOTS-c treatment in two different pathophysiological mechanisms of diabetes in mouse models (β-cell senescence in NOD mice and insulin-antagonist S961-induced insulin-resistant C57BL/6 mice) can reduce senescence in pancreatic β-cells and delay the onset of diabetes.